RxDoctor Payments DataLook up a doctor →

Virgilio Gerald Evidente, MD

Neurology · Scottsdale, AZNPI 1730163353

Payments from drug & device makers

$713,651in general payments, 2019–2025

Across 1,360 payments — averaging $524.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$131K
  • AbbVie$113K
  • Ipsen Pharma SAS$112K
  • Acadia Pharmaceuticals Inc$91K
  • H. Lundbeck A S$83K
  • Sunovion Pharmaceuticals Inc.$59K
  • plus $124K from 40 others
$21,500in research payments, 2019–2025

Across 4 payments — averaging $5375.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Acadia Pharmaceuticals Inc$20K
  • Neurocrine Biosciences, Inc.$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teva Pharmaceuticals USA, Inc.221$131,049
AbbVie(2 entities)117$113,427
Ipsen Pharma SAS68$111,606
Acadia Pharmaceuticals Inc76$90,761
H. Lundbeck A S24$83,161
Sunovion Pharmaceuticals Inc.24$59,197
Integrative Research Laboratories Sweden AB7$41,107
Ipsen Biopharmaceuticals, Inc55$18,831
Neurocrine Biosciences, Inc.54$18,261
UCB, Inc.49$12,066
MDD US Operations, LLC110$7,859
Medtronic(2 entities)103$6,698
Amneal Pharmaceuticals LLC23$5,598
Kyowa Kirin, Inc.38$2,833
Adamas Pharmaceuticals, Inc.24$2,210
Lundbeck LLC11$1,774
Abbott72$1,111
Boston Scientific42$991
Acorda Therapeutics, Inc55$924
Merz Pharmaceuticals, LLC27$751
Cadwell Industries, Inc1$395
Harmony Biosciences LLC8$382
Pfizer27$307
Otsuka America Pharmaceutical, Inc.13$294
Lilly USA, LLC13$286
Eisai Inc.15$228
Merz North America, Inc.10$175
Vertical Pharmaceuticals, LLC7$143
GE HealthCare7$139
Avion Pharmaceuticals7$132
Biohaven Pharmaceuticals, Inc.8$115
Cala Health, Inc.4$102
Biohaven Pharmaceutical Holding Company Ltd.6$99
Scilex Pharmaceuticals Inc.5$98
Avanir Pharmaceuticals, Inc.5$71
Corium, LLC3$69
Noctrix Health, Inc.2$56
Supernus Pharmaceuticals, Inc.2$56
Revance Therapeutics, Inc.3$51
Jazz Pharmaceuticals Inc.3$50
Argenx US, Inc.2$50
Almatica Pharma LLC3$40
Impel Pharmaceuticals Inc.2$38
Biogen2$36
C2n Diagnostics, LLC1$25
Travere Therapeutics, Inc.1$1

How this compares

$713,651 in reported general payments places this provider in the 90th percentile of 388 neurology providers in Arizona.

See all neurology providers in Arizona →

Medicare billing

Part B allowed, 2024
$589,007
Medicare patients
449
Services billed
16,764

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Scottsdale

See the full list for Arizona →

Where these figures come from

Is this you, or does something look wrong? →